Cargando…

The role of MSCs and CAR-MSCs in cellular immunotherapy

Chimeric antigen receptors (CARs) are widely used by T cells (CAR-T cells), natural killer cells dendritic cells and macrophages, and they are of great importance in cellular immunotherapy. However, the use of CAR-related products faces several challenges, including the poor persistence of cells car...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Lun, Li, Jing, Zhang, Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391838/
https://www.ncbi.nlm.nih.gov/pubmed/37528472
http://dx.doi.org/10.1186/s12964-023-01191-4
_version_ 1785082808925945856
author Yan, Lun
Li, Jing
Zhang, Cheng
author_facet Yan, Lun
Li, Jing
Zhang, Cheng
author_sort Yan, Lun
collection PubMed
description Chimeric antigen receptors (CARs) are widely used by T cells (CAR-T cells), natural killer cells dendritic cells and macrophages, and they are of great importance in cellular immunotherapy. However, the use of CAR-related products faces several challenges, including the poor persistence of cells carrying CARs, cell dysfunction or exhaustion, relapse of disease, immune effector cell-associated neurotoxicity syndrome, cytokine release syndrome, low efficacy against solid tumors and immunosuppression by the tumor microenvironment. Another important cell therapy regimen involves mesenchymal stem cells (MSCs). Recent studies have shown that MSCs can improve the anticancer functions of CAR-related products. CAR-MSCs can overcome the flaws of cellular immunotherapy. Thus, MSCs can be used as a biological vehicle for CARs. In this review, we first discuss the characteristics and immunomodulatory functions of MSCs. Then, the role of MSCs as a source of exosomes, including the characteristics of MSC-derived exosomes and their immunomodulatory functions, is discussed. The role of MSCs in CAR-related products, CAR-related product-derived exosomes and the effect of MSCs on CAR-related products are reviewed. Finally, the use of MSCs as CAR vehicles is discussed. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12964-023-01191-4.
format Online
Article
Text
id pubmed-10391838
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-103918382023-08-02 The role of MSCs and CAR-MSCs in cellular immunotherapy Yan, Lun Li, Jing Zhang, Cheng Cell Commun Signal Review Chimeric antigen receptors (CARs) are widely used by T cells (CAR-T cells), natural killer cells dendritic cells and macrophages, and they are of great importance in cellular immunotherapy. However, the use of CAR-related products faces several challenges, including the poor persistence of cells carrying CARs, cell dysfunction or exhaustion, relapse of disease, immune effector cell-associated neurotoxicity syndrome, cytokine release syndrome, low efficacy against solid tumors and immunosuppression by the tumor microenvironment. Another important cell therapy regimen involves mesenchymal stem cells (MSCs). Recent studies have shown that MSCs can improve the anticancer functions of CAR-related products. CAR-MSCs can overcome the flaws of cellular immunotherapy. Thus, MSCs can be used as a biological vehicle for CARs. In this review, we first discuss the characteristics and immunomodulatory functions of MSCs. Then, the role of MSCs as a source of exosomes, including the characteristics of MSC-derived exosomes and their immunomodulatory functions, is discussed. The role of MSCs in CAR-related products, CAR-related product-derived exosomes and the effect of MSCs on CAR-related products are reviewed. Finally, the use of MSCs as CAR vehicles is discussed. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12964-023-01191-4. BioMed Central 2023-08-01 /pmc/articles/PMC10391838/ /pubmed/37528472 http://dx.doi.org/10.1186/s12964-023-01191-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Yan, Lun
Li, Jing
Zhang, Cheng
The role of MSCs and CAR-MSCs in cellular immunotherapy
title The role of MSCs and CAR-MSCs in cellular immunotherapy
title_full The role of MSCs and CAR-MSCs in cellular immunotherapy
title_fullStr The role of MSCs and CAR-MSCs in cellular immunotherapy
title_full_unstemmed The role of MSCs and CAR-MSCs in cellular immunotherapy
title_short The role of MSCs and CAR-MSCs in cellular immunotherapy
title_sort role of mscs and car-mscs in cellular immunotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391838/
https://www.ncbi.nlm.nih.gov/pubmed/37528472
http://dx.doi.org/10.1186/s12964-023-01191-4
work_keys_str_mv AT yanlun theroleofmscsandcarmscsincellularimmunotherapy
AT lijing theroleofmscsandcarmscsincellularimmunotherapy
AT zhangcheng theroleofmscsandcarmscsincellularimmunotherapy
AT yanlun roleofmscsandcarmscsincellularimmunotherapy
AT lijing roleofmscsandcarmscsincellularimmunotherapy
AT zhangcheng roleofmscsandcarmscsincellularimmunotherapy